Phenotypes associated with this allele

• Allele Symbol: Hes1^{tm1(cre/ERT2)Lcm}
• Allele Name: targeted mutation 1, L Charles Murtaugh
• Allele ID: MGI:4412375
• Summary: 4 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Hes1^tm1(cre/ERT2)Lcm/Hes1^tm1(cre/ERT2)Lcm	involves: 129S1/Sv * 129X1/SvJ	MGI:4943522
ht2	Hes1^tm1(cre/ERT2)Lcm/Hes1^+	involves: 129S1/Sv * 129X1/SvJ	MGI:4415725
cn3	Rbpj^tm1Hon/Rbpj^tm1.1Hon Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^+ Hes1^tm1(cre/ERT2)Lcm/Hes1^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:5310799
cn4	Gt(ROSA)26Sor^tm1(Notch1)Dam/Gt(ROSA)26Sor^+ Hes1^tm1(cre/ERT2)Lcm/Hes1^+	involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ	MGI:4943527

Genotype
MGI:4943522

hm1

• Allelic Composition: Hes1^{tm1(cre/ERT2)Lcm}/Hes1^{tm1(cre/ERT2)Lcm}
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:169830 )

• embryos die between E12.5 and E13.5, similar to published Hes1^tm1Fgu knockouts

Genotype
MGI:4415725

ht2

• Allelic Composition: Hes1^{tm1(cre/ERT2)Lcm}/Hes1⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

normal phenotype

no abnormal phenotype detected ( J:169830 )

• heterozygotes are viable and fertile

Genotype
MGI:5310799

cn3

• Allelic Composition: Rbpj^tm1Hon/Rbpj^tm1.1Hon; Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺; Hes1^{tm1(cre/ERT2)Lcm}/Hes1⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:180310 )

N • tamoxifen-treated mice exhibit normal pancreatic ductal morphology and pancreata mass

abnormal centroacinar cell of Langerhans morphology ( J:180310 )

• tamoxifen-treated mice exhibit a decrease in YFP+ centroacinar cells compared with control mice

increased pancreatic acinar cell number ( J:180310 )

• tamoxifen-treated mice exhibit an increase in YFP+ acinar cells compared with control mice

abnormal pancreas physiology ( J:180310 )

• tamoxifen-treated mice exhibit a rapid transformation of YFP+ centroacinar cells into acinar cells compared with control mice

• however, tamoxifen-treated mice exhibit normal centroacinar and acinar cells proliferation and apoptosis

digestive/alimentary system

abnormal centroacinar cell of Langerhans morphology ( J:180310 )

• tamoxifen-treated mice exhibit a decrease in YFP+ centroacinar cells compared with control mice

increased pancreatic acinar cell number ( J:180310 )

• tamoxifen-treated mice exhibit an increase in YFP+ acinar cells compared with control mice

Genotype
MGI:4943527

cn4

• Allelic Composition: Gt(ROSA)26Sor^{tm1(Notch1)Dam}/Gt(ROSA)26Sor⁺; Hes1^{tm1(cre/ERT2)Lcm}/Hes1⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ

endocrine/exocrine glands

abnormal pancreas development ( J:169830 )

• pancreatic progenitor cells (GFP +ve) form cystic structures, not narrow, branched structures, that lack endocrine or acinar marker expression with tamoxifen treatment (2 mg) at E9.5 or 11.5

• treatment at E13.5 or 15.5 blocks islet differentiation, but some exocrine differentiation occurs, with labeled cells integrating into normal acini and ducts

• treatment with 0.5 mg tamoxifen at E9.5 still results in formation of abnormal cystic tubules as seen with the higher dose

• Notch 1 activation at E13.5 results in most GFP +ve cells adopting a ductal, rather than acinar, fate; activation at E15.5 reverses the proportions with most cells taking an acinar fate